Patents by Inventor Nathaniel Eames David

Nathaniel Eames David has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions for targeting muscle cells and uses thereof
    Patent number: 12721902
    Abstract: Disclosed herein are compositions that are useful for targeting a signaling pathway modulator to a muscle cell. In some instances, such compositions may be useful in treating a muscle disorder, such as muscular dystrophy.
    Type: Grant
    Filed: August 13, 2025
    Date of Patent: September 1, 2026
    Assignees: University of Florida Research Foundation, Incorporated
    Inventors: Nathaniel Eames David, Robert N. O'Brien, Timothy R. Stowe, Patrick B. Ventura, James W. West, Elisabeth Barton
  • COMPOSITIONS FOR TARGETING MUSCLE CELLS AND USES THEREOF
    Publication number: 20260041784
    Abstract: Disclosed herein are compositions that are useful for targeting a signaling pathway modulator to a muscle cell. In some instances, such compositions may be useful in treating a muscle disorder, such as muscular dystrophy.
    Type: Application
    Filed: August 13, 2025
    Publication date: February 12, 2026
    Inventors: Nathaniel Eames DAVID, Robert N. O’BRIEN, Timothy R. STOWE, Patrick B. VENTURA, James W. WEST, Elisabeth BARTON
  • IGF-1-RELATED COMPOSITIONS AND USES OF THE SAME
    Publication number: 20260035431
    Abstract: The present disclosure provides composition for use in treating disorders, such as eye disorders (e.g., disorders affecting Meibomian glands). Composition(s) for use in such disorders may act on the IGF-1 pathway, such as by binding to (e.g., agonizing) IGF1R. Such compositions may evade IGF binding proteins. Related methods, kits, and pharmaceutical compositions are also disclosed.
    Type: Application
    Filed: August 14, 2025
    Publication date: February 5, 2026
    Inventors: Nathaniel Eames DAVID, Robert Norman O’BRIEN, Timothy R. STOWE, Jan VAN DEURSEN, James W. WEST, Patrick Brit VENTURA, Janine VAN REE
  • COMPOSITIONS AND METHODS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION
    Publication number: 20250376500
    Abstract: The present disclosure provides composition for use in treating eye-related disorders, such as disorders affecting Meibomian glands. Composition for use in such disorders may act on the IGF-1 pathway, such as by binding to (e.g., agonizing) IGFIR. Other compositions may act on the IGF-1 pathway via another mechanism. Related methods, kits, and pharmaceutical compositions for treating eye-related disorders are also disclosed.
    Type: Application
    Filed: June 18, 2025
    Publication date: December 11, 2025
    Inventors: Nathaniel Eames DAVID, Robert Norman O'BRIEN, Timothy R. STOWE, Jan VAN DEURSEN, James W. WEST, Patrick Brit VENTURA, Janine Hendrike VAN REE
  • COMPOSITIONS AND METHODS FOR TREATING MEIBOMIAN GLAND DYSFUNCTION
    Publication number: 20250368711
    Abstract: The present disclosure provides composition for use in treating eye-related disorders, such as disorders affecting Meibomian glands. Composition for use in such disorders may act on the IGF-1 pathway, such as by binding to (e.g., agonizing) IGF1R. Other compositions may act on the IGF-1 pathway via another mechanism. Related methods, kits, and pharmaceutical compositions for treating eye-related disorders are also disclosed.
    Type: Application
    Filed: August 13, 2025
    Publication date: December 4, 2025
    Inventors: Nathaniel Eames DAVID, Robert Norman O'BRIEN, Timothy R. STOWE, Jan VAN DEURSEN, James W. WEST, Patrick Brit VENTURA, Janine Hendrike VAN REE
  • PROMOTING IMMUNE SURVEILLANCE AGAINST CANCER CELLS
    Publication number: 20240382563
    Abstract: This document provides methods and materials involved in promoting immune surveillance against cancer cells. For example, methods and materials administering one or more chemokine (C-X-C motif) ligand 14 (CXCL 14) polypeptides (and/or nucleic acids designed to encode a CXCL 14 polypeptide) to cancer cells within a mammal (e.g., a human) having cancer to promote immune surveillance against the cancer cells are provided.
    Type: Application
    Filed: July 21, 2022
    Publication date: November 21, 2024
    Inventors: Jan M.A. van Deursen, Hu Li, Ines Sturmlechner, Nathaniel Eames David